Completed PHASE2 INTERVENTIONAL NCT00165191

Doxorubicin, Cisplatin, 5-Fluorouracil in Patients With Advanced Adenocarcinoma of the Stomach or Esophagus

A Phase II Study of Doxorubicin, Cisplatin, and 5-Fluorouracil in Patients With Advanced Adenocarcinoma of the Stomach or Esophagus

Sponsor: Brigham and Women's Hospital

Conditions Adenocarcinoma of Esophagus Adenocarcinoma of GE Junction Adenocarcinoma of Stomach

Interventions 5-fluorouracil Cisplatin Doxorubicin

Updated 5 times since 2017 Last updated: Apr 27, 2009 Started: Aug 31, 1998 Primary completion: Jan 31, 2006 Completion: Jan 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00165191, this PHASE2 trial focuses on Adenocarcinoma of Esophagus and Adenocarcinoma of GE Junction and remains completed. Sponsored by Brigham and Women's Hospital, it has been updated 5 times since 1998, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Aug 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Brigham and Women's Hospital
Dana-Farber Cancer Institute
Massachusetts General Hospital

Data source: Dana-Farber Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States